Neurochemistry and Neuropharmacology of the Cerebellar Ataxias

The predominant (though not exclusive) reference to degenerative ataxias is due to the fact that the specificity of the affected cell populations should allow anticipation of more or less specific neurochemical alterations. This information could be used to look for therapeutic strategies, given the absence of curative treatments for the majority of ataxic disorders. This review covers only the pharmacologic attempts performed to treat ataxic symptoms, and is not exhaustive in terms of nosology, genetics or congenital errors of metabolism. The neurochemical basis of some non-degenerative ataxias that demonstrate favourable responses to pharmacological treatment are also reviewed. An outline of the physiological neurotransmission in the cerebellum opens this chapter (Table 1).

• Publication year

  2012

• Venue

  Unknown venue

• Publication date

  2012-04-18

• Fields of study

  Medicine

• Identifiers
  DOI 10.5772/32406
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Fármacos ansiolíticos y sedantes: farmacología de los trastornos del sueño

  2014cited by this paper
• GABA-A receptor impairment in cerebellar ataxia with anti-glutamic acid decarboxylase antibodies

  2013cited by this paper
• Spinocerebellar Ataxia-Type 3

  2012cited by this paper
• Idebenone in Friedreich ataxia cardiomyopathy-results from a 6-month phase III study (IONIA).

  2011cited by this paper
• Distinct Neurochemical Profiles of Spinocerebellar Ataxias 1, 2, 6, and Cerebellar Multiple System Atrophy

  2011cited by this paper
• The Causes of Epilepsy: Dentato-rubro-pallido-luysian atrophy

  2011cited by this paper
• Generation of Induced Pluripotent Stem Cell Lines from Friedreich Ataxia Patients

  2011influential reference
• Nerve excitability studies characterize Kv1.1 fast potassium channel dysfunction in patients with episodic ataxia type 1.

  2010cited by this paper
• Current and emerging treatment options in the management of Friedreich ataxia

  2010cited by this paper
• Difference in the Effects of Tandospirone on Ataxia in Various Types of Spinocerebellar Degeneration: An Open-Label Study

  2010influential reference
• Carbamylated erythropoietin increases frataxin independent from the erythropoietin receptor

  2010cited by this paper
• A phase 3, double-blind, placebo-controlled trial of idebenone in friedreich ataxia.

  2010cited by this paper
• Cellular and Molecular Pathways Triggering Neurodegeneration in the Spinocerebellar Ataxias

  2010cited by this paper
• Clinical experience with high-dose idebenone in Friedreich ataxia

  2009cited by this paper
• Low-dose idebenone treatment in Friedreich’s ataxia with and without cardiac hypertrophy

  2009cited by this paper
• Spinocerebellar ataxia type 6 (SCA6): clinical pilot trial with gabapentin.

  2009cited by this paper
• Gabapentin treatment improves motor coordination in a mice model of progressive ataxia.

  2009cited by this paper
• Pharmacotherapy for Friedreich Ataxia

  2009cited by this paper
• Late-onset episodic ataxia type 2 associated with a novel loss-of-function mutation in the CACNA1A gene.

  2009cited by this paper
• The efficacy of combined estrogen and buspirone treatment in olivopontocerebellar atrophy.

  2008cited by this paper
• The effect of piracetam on ataxia: clinical observations in a group of autosomal dominant cerebellar ataxia patients

  2008influential reference
• Neurological effects of recombinant human erythropoietin in Friedreich's ataxia: A clinical pilot trial

  2008cited by this paper
• Oxidative stress in neurodegeneration in dentatorubral-pallidoluysian atrophy.

  2008cited by this paper
• Safety, tolerability, and pharmacokinetics of high-dose idebenone in patients with Friedreich ataxia.

  2007cited by this paper
• Friedreich's ataxia: clinical pilot trial with recombinant human erythropoietin

  2007cited by this paper
• Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial.

  2007cited by this paper
• Treatment of spinocerebellar ataxia with buspirone.

  2007influential reference
• Episodic ataxia type 1: A neuronal potassium channelopathy

  2007cited by this paper
• Selective iron chelation in Friedreich ataxia: biologic and clinical implications.

  2007cited by this paper
• Epilepsy and cerebellar ataxia associated with anti-glutamic acid decarboxylase antibodies

  2007cited by this paper
• Neurological, cardiological, and oculomotor progression in 104 patients with Friedreich ataxia during long-term follow-up.

  2007cited by this paper
• Single‐blind, placebo‐controlled pilot study of pregabalin for ataxia in cortical cerebellar atrophy

  2007influential reference
• Olivopontocerebellar atrophy: Toward a better nosological definition

  2006cited by this paper
• Betamethasone and improvement of neurological symptoms in ataxia-telangiectasia.

  2006cited by this paper
• Ataxia-telangiectasia del adulto. Observación clínica y terapéutica

  2006cited by this paper
• CSF analysis differentiates multiple-system atrophy from idiopathic late-onset cerebellar ataxia

  2006influential reference
• Mejoría sintomática de la atrofia olivopontocerebelosa con gabapentina

  2005cited by this paper
• Mutation in the glutamate transporter EAAT1 causes episodic ataxia, hemiplegia, and seizures

  2005cited by this paper
• A genome-wide screen and linkage mapping for a large pedigree with episodic ataxia

  2005cited by this paper
• Clinical and molecular events in patients with Machado–Joseph disease under lamotrigine therapy

  2005cited by this paper
• Sulfamethoxazole-trimethoprim double-blind, placebo-controlled, crossover trial in Machado-Joseph disease: sulfamethoxazole-trimethoprim increases cerebrospinal fluid level of biopterin

  2005influential reference
• Idebenone treatment in Friedreich patients: One-year-long randomized placebo-controlled trial

  2004cited by this paper
• Transient improvement of spinocerebellar ataxia with zolpidem.

  2004cited by this paper
• The cerebellum and its disorders

  2004cited by this paper
• Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis.

  2004cited by this paper
• Treatment of Ataxia in Cortical Cerebellar Atrophy with the GABAergic Drug Gabapentin

  2004cited by this paper
• Positron Emission Tomography

  2004cited by this paper
• Functional implications of a novel EA2 mutation in the P/Q‐type calcium channel

  2004cited by this paper
• Effects of Tandospirone on “5-HT1A Receptor-Associated Symptoms” in Patients with Machado-Josephe Disease: An Open-Label Study

  2004cited by this paper
• A Randomized Double-blind Placebo-controlled Trial

  2004cited by this paper
• D-cycloserine for the treatment of ataxia in spinocerebellar degeneration.

  2003cited by this paper
• Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin’s disease

  2003cited by this paper
• Idebenone treatment in Friedreich’s ataxia

  2003cited by this paper
• Use of fluoxetine for treatment of Machado‐Joseph disease: an open‐label study

  2003influential reference
• Mechanisms underlying cerebellar motor deficits due to mGluR1‐autoantibodies

  2003cited by this paper
• Muscle cramp in Machado-Joseph disease: altered motor axonal excitability properties and mexiletine treatment.

  2003cited by this paper
• High‐dose piracetam is effective on cerebellar ataxia in patient with cerebellar cortical atrophy

  2003cited by this paper
• Reduction of P/Q‐type calcium channels in the postmortem cerebellum of paraneoplastic cerebellar degeneration with Lambert‐Eaton myasthenic syndrome

  2003influential reference
• Double-blind crossover study of branched-chain amino acid therapy in patients with spinocerebellar degeneration.

  2002cited by this paper
• Alcohol toxicity in the cerebellum: clinical aspects

  2002cited by this paper
• Modulation of cerebral GABA by topiramate, lamotrigine, and gabapentin in healthy adults

  2002cited by this paper
• Greenfield's Neuropathology

  2002cited by this paper
• Clorhidrato de buspirona en el tratamiento de la ataxia cerebelosa

  2002cited by this paper
• Gangliosidosis GM2 del adulto: mejoría de la ataxia con fármacos GABAérgicos

  2002cited by this paper
• P/Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer

  2002influential reference
• An autoantibody to GAD65 in sera of patients with juvenile neuronal ceroid lipofuscinoses

  2002cited by this paper
• Oligodendrocytic polyglutamine pathology in dentatorubral‐pallidoluysian atrophy

  2002cited by this paper
• [Hereditary ataxias and paraplegias: a clinicogenetic review].

  2002cited by this paper
• Friedreich's Ataxia: Idebenone Treatment in Early Stage Patients

  2002cited by this paper
• The Cerebellum and its Disorders: Episodic ataxias as ion channel diseases

  2001influential reference
• Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients.

  2001cited by this paper
• Biogenic Amine Metabolites and Thiamine in Cerebrospinal Fluid in Heredo-Degenerative Ataxias

  2001influential reference
• The Cerebellum and its Disorders: Multiple system atrophy and idiopathic late-onset cerebellar ataxia

  2001cited by this paper
• The Cerebellum and its Disorders: Cerebellar disorders in cancer

  2001cited by this paper
• Cancer and the nervous system

  2001cited by this paper
• [Structure and function of the cerebellum].

  2001cited by this paper
• Double-blind crossover trial of trimethoprim-sulfamethoxazole in spinocerebellar ataxia type 3/Machado-Joseph disease.

  2001influential reference
• The Cerebellum and its Disorders: SPORADIC DISEASES

  2001cited by this paper
• The Cerebellum and its Disorders: Neuropathology of the inherited ataxias

  2001cited by this paper
• An autosomal dominant disorder with episodic ataxia, vertigo, and tinnitus

  2001cited by this paper
• Clinical trial of acetazolamide in SCA6, with assessment using the Ataxia Rating Scale and body stabilometry

  2001cited by this paper
• The Cerebellum and its Disorders: Neuroanatomy of the cerebellum

  2001cited by this paper
• Gaba in the nervous system : the view at fifty years

  2000cited by this paper
• Coding and noncoding variation of the human calcium-channel beta4-subunit gene CACNB4 in patients with idiopathic generalized epilepsy and episodic ataxia.

  2000cited by this paper
• Neurotransmitters, Neuropeptides and Calcium Binding Proteins in Developing Human Cerebellum: A Review

  2000cited by this paper
• Evolution of sporadic olivopontocerebellar atrophy into multiple system atrophy

  2000cited by this paper
• Double-Blind, Crossover, Placebo-Controlled Clinical Trial with L-Acetylcarnitine in Patients with Degenerative Cerebellar Ataxia

  2000cited by this paper
• Molecular basis of Friedreich ataxia

  2000cited by this paper
• Mechanisms of action of anticonvulsant agents.

  2000cited by this paper
• Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study.

  1999cited by this paper
• Selective suppression of cerebellar GABAergic transmission by an autoantibody to glutamic acid decarboxylase

  1999influential reference
• Spinocerebellar ataxia type 6 with positional vertigo and acetazolamide responsive episodic ataxia

  1998cited by this paper
• Autoantibodies to glutamate receptor subunit GluR2 in nonfamilial olivopontocerebellar degeneration

  1997cited by this paper
• Buspirone, a 5-hydroxytryptamine1A agonist, is active in cerebellar ataxia. Results of a double-blind drug placebo study in patients with cerebellar cortical atrophy.

  1997cited by this paper
• Double-blind crossover study with physostigmine in patients with degenerative cerebellar diseases.

  1997influential reference
• Calcium channels in neurological disease

  1997influential reference
• Autoantibodies to glutamic acid decarboxylase in three patients with cerebellar ataxia, late-onset insulin-dependent diabetes mellitus, and polyendocrine autoimmunity

  1997cited by this paper
• Analysis of fast single-joint and multijoint movements in cerebellar cortical atrophy: failure of L-hydroxytryptophan to improve cerebellar ataxia.

  1997cited by this paper
• International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology.

  1997influential reference
• The inherited ataxias and the new genetics.

  1996cited by this paper

• No citing papers are available for this paper.